NEW YORK, Jan. 28, 2020 /PRNewswire/ -- TrialJectory,
an AI-powered technology platform that empowers cancer patients to
search and match with clinical trials, removing barriers to
advanced treatment options, today announced that the Company has
launched a new partnership with specialty cancer diagnostics
company Precipio, Inc. (NASDAQ: PRPO) to provide cancer patients
worldwide with a first-of-its-kind diagnostic and clinical
trial-matching service that assists doctors in providing the best
possible treatment for their patients.
"Cancer patients face two significant obstacles when it comes to
effectively managing their disease: first, the danger of
misdiagnosis and, second, finding the right clinical trial for
them," said Ilan Danieli, CEO of
Precipio. "As Precipio and TrialJectory share an ongoing commitment
to advancing patient care, we formed this partnership to take the
innovations of both companies and combine them to improve patient
treatment outcomes. Not only are patients entitled to receive an
accurate diagnosis at the start of their battle with cancer, but
they also deserve access to match and enroll in the best clinical
trials available for their unique situation – without having to
struggle through the complex matching and enrollment process.
Precipio and TrialJectory's collaboration provides physicians and
patients with a powerful new resource that delivers immediate,
hassle-free, personalized matching to relevant clinical trials,
enhancing overall survival for patients."
With this partnership, Precipio's comprehensive diagnostic
result reports will now include a personalized list of relevant
clinical trials matched to the patient based on the trials'
eligibility requirements, which are generated by TrialJectory's
AI-based clinical trial-matching platform. The platform uses
patient clinical information to facilitate the clinical trial
search, matching and enrollment by patients and their physicians.
If patients decide to further explore one or more of the matched
trials, TrialJectory facilitates, on behalf of the patient, all
communication with the clinical trial lead, including document
collection, appointment scheduling and more.
"While this partnership offers enormous benefits for both
patients and physicians, it ultimately allows patients to take back
control of their health and empowers them to make decisions that
are right for them based on accurate information from advanced new
technologies," added Tzvia Bader,
CEO and co-founder, TrialJectory. "We look forward to working
closely with Precipio in the months and years to come to aid in
providing the best possible treatment for cancer patients
everywhere."
About TrialJectory
TrialJectory is an AI-based
clinical trial-matching platform that facilitates the clinical
trial search, enrollment and engagement by cancer patients and
their physicians. The Company partners with all sectors of the
health industry to revolutionize the trial recruitment and
engagement process, leading to reduced operational costs and
expedited drugs' time to market. For more information, please visit
www.trialjectory.com.
About Precipio
Precipio has built a platform designed
to eradicate the problem of misdiagnosis by harnessing the
intellect, expertise and technology developed within academic
institutions and delivering quality diagnostic information to
physicians and their patients worldwide. Through its collaborations
with world-class academic institutions specializing in cancer
research, diagnostics and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute and the
University of Pennsylvania, Precipio
offers a new standard of diagnostic accuracy enabling the highest
level of patient care. For more information, please visit
www.precipiodx.com.
View original
content:http://www.prnewswire.com/news-releases/trialjectory-and-precipio-partner-to-provide-cancer-patients-with-first-of-its-kind-diagnostic-and-clinical-trial-matching-service-300993974.html
SOURCE TrialJectory